With essential tremor, life doesn’t always go the way you pictured.

As you know, essential tremor can impact everyday activities. The KINETIC 2 TRIAL is studying the potential efficacy on tremor reduction of three different doses of an investigational drug as compared to placebo. A placebo is an inactive pill that looks like the investigational drug, but contains no active medication. The safety and efficacy of investigational drugs have not been established. There is no guarantee that this drug will be approved by a health authority, such as the US Food and Drug Administration (FDA).

If you have been diagnosed with essential tremor for at least three years, you may be eligible to participate.

See if you may be eligible

See if you may be eligible.

We are enrolling adults ages 18 to 80 years old who have been formally diagnosed with essential tremor. If you are interested in taking part in this clinical study, please continue below and complete the questionnaire to see if you may be eligible.

Step 1 of 3

Consent.

By answering the following questions, you agree to have your information retained for the duration of this study, and to receiving phone or email communication(s) related to this clinical research study.

e.g., 12345

MM/DD/YYYY

This website uses Secure Socket Layer technology and encryption methods to protect personal health information. If you’d like to know more about our privacy policy, click here.

Step 2 of 3

Have you been diagnosed by a medical professional with essential tremor?
How long ago were you diagnosed with essential tremor?
Have you had a previous procedure for your essential tremor (for example, deep brain stimulation, brain lesioning, or magnetic resonance–guided procedure)?
Have you received botulinum toxin for treatment of upper limb tremor within the past six months?
Are you currently taking any of the following medications to treat your essential tremor?
Have you participated in a clinical trial within the past 30 days?
Have you experienced significant blood loss or donated blood within the past 60 days?
Study duration for participants lasts approximately 19 weeks. Do you plan to undergo elective surgery or relocate during your time participating in the study?
Have you previously participated in a clinical study of SAGE-324?

By submitting this questionnaire, you are agreeing to have your information retained for the duration of this study, as well as to having a study site contact you.

This website uses Secure Socket Layer technology and encryption methods to protect personal health information. If you’d like to know more about our privacy policy, click here.